NCCN 6th Annual Congress on Hematologic Malignancies

 
 
 

NCCN 6th Annual Congress on Hematologic Malignancies

 

PTLD rare but important complication of transplant

Alice Goodman Read Article
Published: 09/22/11

bone_marrow_aspirate_showing_HSCs.jpg
Hematopoietic stem cells
from bone marrow aspirate

Post-transplant lymphoproliferative disorder (PTLD) has emerged as a significant complication of solid organ and allogeneic bone marrow transplant. And the single biggest risk factor for PTLD is a mismatch in Epstein-Barr virus (EBV) status between the recipient and the donor. Ann S. LaCasce, MD, of the Dana-Farber Cancer Institute, reviewed management options for PTLD at the NCCN 6th Annual Congress on Hematologic Malignancies. [Read Article]

Is maintenance a one-size-fits-all proposition in MM?

Erilyn Riley Read Article
Published: 09/21/11

Devine_Stephen MD_NCCN 2011.jpg
Stephen Devine, MD

NCCN guidelines recommend maintenance therapy with thalidomide, lenalidomide, or bortezomib for patients with multiple myeloma. But the guidelines make no suggestions regarding the optimal dose, duration, or advisability for patients with relapsed or refractory disease. Steven Devine, MD, put some of the evolving trial data on maintenance therapy into perspective at the NCCN 6th Annual Congress on Hematologic Malignancies. [Read Article]

When CLL patients require treatment…

Erilyn Riley Read Article
Published: 09/15/11

O'Brien_Susan_MD_NCCN 2011.jpg
Susan O'Brien, MD

Observation is still the standard of care for asymptomatic chronic lymphocytic leukemia (CLL) patients, but is it a good strategy for patients with poor-risk cytogenetics? Would earlier intervention be beneficial? Susan O’Brien, MD, of the University of Texas MD Anderson Cancer Center, provided some direction for making treatment decisions based on patient characteristics at the NCCN 6th Annual Congress on Hematologic Malignancies. [Read Article]

What about maintenance therapy in B-cell lymphoma?

Erilyn Riley Read Article
Published: 09/12/11

Zelenetz_Andrew D._MD, PhD_NCCN 2011.jpg
Andrew D. Zelenetz, MD, PhD

The question of maintenance therapy in B-cell lymphoma has a clear-cut answer for aggressive lymphoma—there is no advantage, according to Andrew D. Zelenetz, MD, PhD, of Memorial Sloan-Kettering Cancer Center. But for follicular lymphoma, it’s another matter. Dr Zelenetz presented data on maintenance in follicular lymphoma at the recent NCCN 6th Annual Congress on Hematologic Malignancies. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}